September 20, 2012
Torii Pharmaceutical announced on September 14 the preliminary results of a domestic PIII clinical trial for TO-194SL, a sublingual immunotherapy (hyposensitization) drug for cedar pollen allergy. In the trial, the drug alleviated symptoms of cedar pollen allergy with a statistically...read more